6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Impaired oxidative stress response characterizes HUWE1-promoted X-linked intellectual disability

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mutations in the HECT, UBA and WWE domain-containing 1 ( HUWE1) E3 ubiquitin ligase cause neurodevelopmental disorder X-linked intellectual disability (XLID). HUWE1 regulates essential processes such as genome integrity maintenance. Alterations in the genome integrity and accumulation of mutations have been tightly associated with the onset of neurodevelopmental disorders. Though HUWE1 mutations are clearly implicated in XLID and HUWE1 regulatory functions well explored, currently much is unknown about the molecular basis of HUWE1-promoted XLID. Here we showed that the HUWE1 expression is altered and mutation frequency increased in three different XLID individual (HUWE1 p.R2981H, p.R4187C and HUWE1 duplication) cell lines. The effect was most prominent in HUWE1 p.R4187C XLID cells and was accompanied with decreased DNA repair capacity and hypersensitivity to oxidative stress. Analysis of HUWE1 substrates revealed XLID-specific down-regulation of oxidative stress response DNA polymerase (Pol) λ caused by hyperactive HUWE1 p.R4187C. The subsequent restoration of Polλ levels counteracted the oxidative hypersensitivity. The observed alterations in the genome integrity maintenance may be particularly relevant in the cortical progenitor zones of human brain, as suggested by HUWE1 immunofluorescence analysis of cerebral organoids. These results provide evidence that impairments of the fundamental cellular processes, like genome integrity maintenance, characterize HUWE1-promoted XLID.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          De novo mutations in human genetic disease.

          New mutations have long been known to cause genetic disease, but their true contribution to the disease burden can only now be determined using family-based whole-genome or whole-exome sequencing approaches. In this Review we discuss recent findings suggesting that de novo mutations play a prominent part in rare and common forms of neurodevelopmental diseases, including intellectual disability, autism and schizophrenia. De novo mutations provide a mechanism by which early-onset reproductively lethal diseases remain frequent in the population. These mutations, although individually rare, may capture a significant part of the heritability for complex genetic diseases that is not detectable by genome-wide association studies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

            Although the importance of the ARF tumor suppressor in p53 regulation is well established, numerous studies indicate that ARF also suppresses cell growth in a p53/Mdm2-independent manner. To understand the mechanism of ARF-mediated tumor suppression, we identified a ubiquitin ligase, ARF-BP1, as a key factor associated with ARF in vivo. ARF-BP1 harbors a signature HECT motif, and its ubiquitin ligase activity is inhibited by ARF. Notably, inactivation of ARF-BP1, but not Mdm2, suppresses the growth of p53 null cells in a manner reminiscent of ARF induction. Surprisingly, in p53 wild-type cells, ARF-BP1 directly binds and ubiquitinates p53, and inactivation of endogenous ARF-BP1 is crucial for ARF-mediated p53 stabilization. Thus, our study modifies the current view of ARF-mediated p53 activation and reveals that ARF-BP1 is a critical mediator of both the p53-independent and p53-dependent tumor suppressor functions of ARF. As such, ARF-BP1 may serve as a potential target for therapeutic intervention in tumors regardless of p53 status.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              De novo mutations of SETBP1 cause Schinzel-Giedion syndrome.

              Schinzel-Giedion syndrome is characterized by severe mental retardation, distinctive facial features and multiple congenital malformations; most affected individuals die before the age of ten. We sequenced the exomes of four affected individuals (cases) and found heterozygous de novo variants in SETBP1 in all four. We also identified SETBP1 mutations in eight additional cases using Sanger sequencing. All mutations clustered to a highly conserved 11-bp exonic region, suggesting a dominant-negative or gain-of-function effect.
                Bookmark

                Author and article information

                Contributors
                barbara.v.loon@ntnu.no
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                8 November 2017
                8 November 2017
                2017
                : 7
                : 15050
                Affiliations
                [1 ]ISNI 0000 0004 1937 0650, GRID grid.7400.3, Department of Molecular Mechanisms of Disease, University of Zurich, ; Zürich, 8057 Switzerland
                [2 ]ISNI 0000 0001 1516 2393, GRID grid.5947.f, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), ; Trondheim, 7491 Norway
                [3 ]Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, 0318 Norway
                [4 ]ISNI 0000000121885934, GRID grid.5335.0, Department of Medical Genetics, Cambridge Institute for Medical Research, ; Cambridge, CB2 0XY United Kingdom
                [5 ]Human Genome Laboratory, Department of Human Genetics, Leuven, 3000KU Belgium
                [6 ]ISNI 0000 0004 0627 3560, GRID grid.52522.32, Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital, ; Trondheim, 7491 Norway
                [7 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, CRUK/MRC Institute for Radiation Oncology, Department of Oncology, University of Oxford, ; Oxford, OX3 7DQ United Kingdom
                [8 ]GRID grid.418953.2, Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, ; Novosibirsk, 630090 Russia
                Article
                15380
                10.1038/s41598-017-15380-y
                5678168
                29118367
                07c854d2-3a5e-4340-a6f1-5f77e262f955
                © The Author(s) 2017

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 4 September 2017
                : 25 October 2017
                Categories
                Article
                Custom metadata
                © The Author(s) 2017

                Uncategorized
                Uncategorized

                Comments

                Comment on this article